Stem-cell transplantation in T-cell non-Hodgkin's lymphomas

Abstract

Background: T-cell lymphomas are a heterogeneous group of non-Hodgkin's lymphomas (NHLs). With the exception of anaplastic lymphoma kinase protein-positive large-cell lymphoma, standard chemotherapy provides dismal long-term outcomes when compared with NHLs with B-cell immunophenotype. Design: We review the literature on the role of high-dose chemotherapy (HDT) and autologous stem-cell transplantation (ASCT) in T-cell NHLs both as up-front treatment and in the salvage setting. The role of allogeneic transplantation will also be reviewed. Results: Results from five prospective, nonrandomized and six retrospective studies evaluating the role of HDT and ASCT in the up-front setting show that patients in first complete or partial remission especially those who present with advanced disease and high prognostic index of peripheral T-cell lymphoma score may benefit from this approach. In the relapsed and/or refractory setting, most series show results that are comparable with those seen in patients with B-cell lymphomas if transplanted with chemosensitive disease. There is limited evidence to suggest that an immunemediated graft-versus-lymphoma effect may result in long-term disease remissions in some patients after allogeneic transplantation. Conclusions: Randomized studies comparing HDT and ASCT with conventional chemotherapy are needed in T-cell lymphomas. © The Author 2011. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.